Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16254592 | 0.83 | F2R (0.41) | F2RKDM5ARAB9ACNR2CYP2D6 | |
| SCHEMBL16252578 | 0.80 | MAPT (0.46) | F2RKDM5APOLB | |
| SCHEMBL15161372 | 0.75 | CA1 (0.48) | F2RALDH1A1 | |
| SCHEMBL10208258 | 0.75 | CHRNB2 (0.42) | KDM5AMTNR1AMTNR1B | |
| SCHEMBL16252583 | 0.74 | KDM5A (0.39) | KDM5AMTNR1AMTNR1B | |
| SCHEMBL16252587 | 0.74 | KDM5A (0.39) | KDM5AMTNR1AMTNR1B | |
| SCHEMBL16252580 | 0.74 | KDM5A (0.39) | KDM5AMTNR1AMTNR1B | |
| SCHEMBL17453343 | 0.73 | POLB (0.49) | POLBALDH1A1MTNR1AMTNR1BKDM4E | |
| SCHEMBL22916946 | 0.73 | CHRNB2 (0.50) | KDM5AMTNR1AMTNR1B | |
| SCHEMBL10210690 | 0.73 | KDM4E (0.39) | KDM5AMTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | F2R 3193/4885KDM5A 2759/4885POLB 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.